S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
NASDAQ:NMTR

9 Meters Biopharma (NMTR) Stock Forecast, Price & News

$0.01
-0.01 (-45.45%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.01
$0.02
50-Day Range
$0.01
$0.13
52-Week Range
$0.07
$6.56
Volume
10,046 shs
Average Volume
315,915 shs
Market Capitalization
$172,032.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.35

NMTR stock logo

About 9 Meters Biopharma (NASDAQ:NMTR) Stock

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

NMTR Price History

NMTR Stock News Headlines

9 Meters Biopharma (OTC: NMTR.Q)
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
Why Are 9 Meters Biopharma Shares Nosediving Today?
Temperato resigns as CEO of Raleigh drugmaker
9 Meters Biopharma (NASDAQ: NMTR)
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
NMTR - 9 Meters Biopharma, Inc.
Why this Raleigh pharma just cut half its workforce
NMTR 9 Meters Biopharma, Inc.
Raleigh pharma raises $5M as phase 3 study begins
Energy bills: 'I was forced onto a prepayment meter'
See More Headlines
Receive NMTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.

NMTR Company Calendar

Last Earnings
11/15/2021
Today
9/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NMTR
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.35
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$1.70
Forecasted Upside/Downside
+152,816.7%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-43,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.19 per share

Miscellaneous

Free Float
13,992,000
Market Cap
$172,032.00
Optionable
Optionable
Beta
1.36
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Ms. Bethany Sensenig C.M.A. (Age 47)
    M.B.A., Interim CEO & CFO
    Comp: $525.59k
  • Dr. Peter H. R. Green M.D.
    Clinical & Scientific Advisor and Consultant
  • Mr. Joseph A. Murray M.D.
    Clinical & Scientific Advisor and Consultant
  • Dr. Ciaran P. Kelly M.D.
    Clinical & Scientific Advisor and Consultant
  • Dr. Elena Verdu M.D.
    Ph.D., Clinical & Scientific Advisor and Consultant
  • Mr. Markku Mäki M.D.
    Ph.D., Clinical & Scientific Advisor and Consultant
  • Dr. William J. Sandborn M.D. (Age 60)
    Ph.D., Clinical & Scientific Advisor and Consultant
  • Dr. Roger Liddle M.D.
    Clinical & Scientific Advisor and Consultant
  • Dr. Anthony J. Dimarino Jr.
    Clinical & Scientific Advisor and Consultant
  • Dr. Brian Gordon Feagan FRCPC
    M.D., M.P.H., Clinical & Scientific Advisor and Consultant













NMTR Stock - Frequently Asked Questions

Should I buy or sell 9 Meters Biopharma stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares.
View NMTR analyst ratings
or view top-rated stocks.

What is 9 Meters Biopharma's stock price forecast for 2023?

4 equities research analysts have issued 1-year target prices for 9 Meters Biopharma's stock. Their NMTR share price forecasts range from $1.70 to $35.00. On average, they expect the company's share price to reach $18.35 in the next year. This suggests a possible upside of 152,816.7% from the stock's current price.
View analysts price targets for NMTR
or view top-rated stocks among Wall Street analysts.

How have NMTR shares performed in 2023?

9 Meters Biopharma's stock was trading at $1.26 at the start of the year. Since then, NMTR stock has decreased by 99.0% and is now trading at $0.0120.
View the best growth stocks for 2023 here
.

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.26.

When did 9 Meters Biopharma's stock split?

9 Meters Biopharma's stock reverse split before market open on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of 9 Meters Biopharma own?
What is 9 Meters Biopharma's stock symbol?

9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR."

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 9 Meters Biopharma's stock price today?

One share of NMTR stock can currently be purchased for approximately $0.01.

How much money does 9 Meters Biopharma make?

9 Meters Biopharma (NASDAQ:NMTR) has a market capitalization of $172,032.00. The company earns $-43,770,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How can I contact 9 Meters Biopharma?

9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The official website for the company is www.9meters.com. The company can be reached via phone at (919) 275-1933 or via email at investor-relations@9meters.com.

This page (NASDAQ:NMTR) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -